Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3322819 | 0.84 | HSD11B1 (0.55) | KMT2AMEN1P2RX7POLBHSD11B1 | |
| SCHEMBL3321995 | 0.81 | P2RX7 (0.74) | KMT2AMEN1SMN1; SMN2P2RX7POLB | |
| SCHEMBL9373354 | 0.75 | HDAC3 (0.51) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL3323255 | 0.73 | KMT2A (0.60) | KMT2AMEN1SMN1; SMN2P2RX7POLB | |
| SCHEMBL3327631 | 0.73 | HSD11B1 (0.67) | KMT2AMEN1SMN1; SMN2P2RX7POLB | |
| SCHEMBL13361624 | 0.68 | KMT2A (0.53) | KMT2AMEN1SMN1; SMN2P2RX7POLB | |
| SCHEMBL3322028 | 0.68 | KMT2A (1.00) | KMT2AMEN1SMN1; SMN2P2RX7POLB | |
| SCHEMBL5556786 | 0.67 | MMP9 (0.49) | — | |
| SCHEMBL5663650 | 0.66 | KDM4E (0.59) | KMT2AMEN1POLBALDH1A1RAB9A | |
| SCHEMBL3327366 | 0.66 | KMT2A (0.63) | KMT2AMEN1SMN1; SMN2P2RX7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | KMT2A 3083/4885MEN1 3474/4885SMN1; SMN2 4801/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | KMT2A 2533/4885MEN1 2608/4885SMN1; SMN2 4612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.